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Summary 
Background. Delirium in the critically ill is associated with poor clinical outcomes. It is 
believed that neuroinflammation is an important mechanism in the pathogenesis of delirium. 
Simvastatin has anti-inflammatory properties and may reduce delirium. The aim of this study 
was to establish whether early treatment with simvastatin would decrease the time that 
survivors of critical illness spent in delirium or coma. 
Methods. This double-blind, placebo-controlled randomised trial was conducted in a general 
adult intensive care unit (ICU). Critically ill patients (≥18 years) needing mechanical 
ventilation within 72 h of admission were enrolled. Patients were randomised in a 1:1 ratio to 
receive either simvastatin 80mgs or placebo daily for up to a maximum of 28 days treatment, 
irrespective of coma or delirium status. Delirium was assessed using the confusion 
assessment method for the ICU (CAM-ICU). The primary outcome was alive, delirium-free 
and coma-free days, in the first 14 days after randomisation. ICU clinical and research staff 
and patients were blinded to treatment. Analyses were by intention to treat and no 
extrapolation was performed. This trial was registered with the International Standard 
Randomised Controlled Trial Registry, number ISRCTN89079989. 
Findings. One hundred and forty-two patients were randomised, and included in the final 
analysis, 71 simvastatin, and 71 placebo. The mean number of days alive without delirium 
and without coma at day 14 did not differ significantly between the two groups (5·7 ± 5·1 
days with simvastatin and 6·1 ± 5·2 days with placebo; mean difference, 0 days [95% CI, -
1·3 to 2·1]; P = 0·66). The most common adverse event was an elevated creatine kinase to 
over ten times the upper limit of normal (eight (11·3%) in the simvastatin group vs. three 
(4.2%) in the placebo group p=0·208). No patient had a serious adverse event related to the 
study drug. 
Interpretation. These results do not support the hypothesis that simvastatin modifies duration 
of delirium and coma in critically ill patients.  
Funding.  National Institute for Health Research. 
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Research in context 
 
Systematic review 
 
We searched PubMed, MEDLINE, and the Cochrane Database of Systematic Reviews 
without language or date restrictions for published research that assessed the use of statins 
for mechanically ventilated patients in intensive care units with delirium as either the primary 
or a secondary outcome. The most recent search was done on 19th March, 2017. We 
searched PubMed with the key words “intensive care”, “critical care”, “delirium”, and 
“statins”.  We included only studies in adult patients.  
A systematic review and meta-analysis evaluating the role of statins in the prevention of 
delirium in critically ill and cardiac surgical patients included six studies. While it did not show 
a benefit with statin therapy all of the studies included were observational. A preplanned 
secondary analysis of the SAILS trial dataset, a randomised controlled trial of rosuvastatin 
versus placebo in patients with sepsis-associated acute respiratory distress syndrome, 
assessed the impact on delirium in 272 patients. It showed no benefit of rosuvastatin in 
reducing delirium or cognitive impairment during 12 months of follow up. The study was not 
powered for superiority and in view of the low lipophilicity of rosuvastatin the study was 
unable to conclude that a different statin would not be beneficial. 
There are no relevant Cochrane reviews for delirium. 
Added value of this study 
This randomised controlled trial evaluated the effects of enteral simvastatin on delirium in 
critically ill mechanically ventilated patients. Simvastatin did not modify the duration of brain 
dysfunction according to number of patient days assessed to be in coma and days in 
delirium. Its use is not recommended for the management of delirium in this patient 
population. 
Implications of all the available evidence 
Simvastatin is not beneficial in increasing the number of days patients spend without coma or 
delirium in this vulnerable population at high risk of delirium. Statins should not be used in the 
management of critically ill patients at risk of, or with delirium. 
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Background  
 
Delirium is a clinical syndrome characterised by acute brain dysfunction and associated with 
worse outcomes including long-term cognitive impairment, increased length of hospital stay 
and costs.1-4 The prevalence of delirium in patients in critical care is reported to be up to 
74% in critically ill patients with a high severity of illness and approximately 50% in patients 
who require mechanical ventilation or over 48 hours.3,4 There is evidence in animal and 
human studies that neuroinflammation is a contributing factor to long term cognitive 
imparirment.5   Literature includes a relationship between elevated serum inflammatory 
markers in critically ill patients regardless of the presence of sepsis,6 higher levels of 
CSF:serum IL-1β ratios in delirious than non-delirious patients and an upregulation of CNS 
inflammation in patients who died with delirium unrelated to infection.7,8 
 No medications that have been shown to prevent or reduce delirium in mechanically 
ventilated, critically ill adults, studies undertaken in elective cardiac surgical patients are not 
applicable to this population. Statins, in addition to decreasing cholesterol synthesis, have 
complex pleiotropic effects.9 These pleiotropic effects may prevent or attenuate delirium in 
critical illness by acting on causative mechanisms including neuroinflammation, blood-brain 
barrier injury, neuronal apoptosis, ischaemia, haemorrhage and microglia activation. In vitro 
and animal studies have shown that statins suppress the up-regulation of toll- like receptors 
(which trigger inflammation) and reduce the release of TNF-α, IL-1β and MCP-1 as well as 
leukocyte adhesion molecules implicated in the development of endothelial damage and 
blood-brain barrier alterations.10 In animal studies statins have been shown to preserve post-
operative memory retrieval and in traumatic brain injury to increase hippocampal neuron 
survival with improved neurological function.11  
Two large cohort observational studies found an association between reduction of the risk of 
delirium in critically ill patients with ongoing use but not pre-hospital statin alone raising the 
hypothesis that statins would potentially decrease delirium in this patient population.12, 13 An 
in vitro study comparing different statins for prevention of neurodegenerative conditions 
concluded that monacolin J derivatives (natural and semi-synthetic statins), which includes 
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simvastatin, were the most beneficial due to better lipophilicity and capacity to penetrate the 
blood–brain barrier. 14  A preplanned secondary analysis of days in delirium was undertaken 
as part of a study in to determine the effects of statin therapy on mortality in mechanically 
ventilated patients with acute respiratory distress syndrome.15 Rosuvastatin, known to be 
relatively hydrophilic, was used and there was no improvement in days spent in delirium or 
cognitive outcomes. 
The aim of the Modifying Delirium Using Simvastatin (MoDUS) trial was to test the 
hypothesis that treatment with enteral for a maximum of 28 days will increase the number of 
days alive and assessed as being delirium-free and coma-free, in mechanically ventilated 
patients at high risk of delirium.  
 
Methods 
 
This was a randomised, double-blind, placebo-controlled trial of enteral simvastatin in adult 
(≥ 18 years) mechanically ventilated patients. Patients were recruited from the general mixed 
medical–surgical adult ICU in Watford General Hospital (Watford, UK).  
The trial was approved by a national research ethics committee (12/NE/0383) and the 
MHRA (CTA number 18300/0002/001-0001and EudraCT Number: 2012-003114-13) and 
research governance department at West Hertfordshire Hospitals NHS Trust. The trial was 
registered on the International Standard Randomised Controlled Trial Registry 
(ISRCTN89079989). The trial was sponsored by West Hertfordshire Hospitals NHS Trust 
and was coordinated by the Northern Ireland Clinical Trials Unit (CTU). The trial design has 
been published in detail previously
 
and the trial protocol and is available in the online 
supplement.16 The trial is reported in line with the Consolidated Standards of Reporting 
Trials (CONSORT) guidelines.17 
 
Patients 
Patients receiving invasive mechanical ventilation within the first 72 hours of ICU admission 
were eligible for inclusion in the study. The main exclusion criteria are listed in Figure 1 and 
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the full list is provided in the study protocol. The eligibility criterion for creatinine clearance 
was decreased from 30 ml/minute to 15 ml/minute on 22nd July 2015. Patients or their 
representatives provided written informed consent. 
 
Randomisation and masking 
 
The dosage of simvastatin administered in this trial was chosen based on data from a 
retrospective observational study of statin usage in patients with sepsis, which showed a 
greater mortality benefit in patients who were receiving a higher dose of statin.18 A nested 
cohort study found that statin therapy reduced hospital mortality in patients with sepsis only 
when higher doses of statins, in particular simvastatin, were given.19 Moreover, simvastatin 
at a dose of 80 mg is well tolerated in acute lung injury patients, with no increase in adverse 
events.20 A multi-centre prospective cohort study that included 197 ICU statin users reported 
simvastatin was the most frequent statin drug used with a median dose of 40mg 
(interquartile range 20mgs to 80 mgs).12 
Patients were randomly assigned in a 1:1 ratio to receive either 80mgs simvastatin or 
identical placebo enterally. The study statistician generated the randomisation schedule in 
advance using nQuery Advisor, randomisation was by variable block size, without 
stratification. Patient drug packs were prepared by Victoria Pharmaceuticals according to the 
prearranged order and distributed to site. Each pack was numbered with a unique patient 
trial identifier allocated to each patient at the time of randomisation. Study drug packs were 
stored by hospital pharmacy in a secure area and dispensed by pharmacy to ICU as 
required.  
Simvastatin 40mg or identical placebo tablets were packaged in white opaque HDPE plastic 
containers sealed with a tamper-evident seal. The placebo and active tablets were 
indistinguishable when crushed and dispersed in water for enteral administration. All ICU 
clinical and research staff, legal representatives, and the patients were masked to study 
drug. The data monitoring and safety committee reviewed blinded data reports. The study 
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statisticians were not masked to allocation. The success of blinding was not formally 
assessed. 
 
Procedures 
 
Demographic characteristics were recorded at the time of enrolment. The risk of developing 
delirium during critical care admission was calculated using the PRE-DELIRIC delirium 
prediction model.21 Data were recorded daily while the patient remained in ICU up to a 
maximum of 28 days. Treatment was initiated within 72 h of admission to ICU, irrespective of 
the presence of coma or delirium. 
Patients received the study drug via a feeding tube or orally daily. The first dose of the study 
drug was administered as soon as possible and ideally within 4 hours after randomisation. 
For all subsequent days the study drug was given at midday. Study drug was discontinued 
on ICU discharge, after a maximum of 28 days treatment, death, discharge, creatine kinase 
10 times more than the upper limit of normal, alanine transaminase eight times upper limit of 
normal, development of a clinical condition requiring immediate treatment with statin, 
discontinuation of active treatment, request for discontinuation by patient or legal 
representative, request for discontinuation by attending clinician or contraindication to 
enteral drug administration. 
Patients were sedated using fentanyl and propofol infusions titrated to a Richmond agitation 
sedation scale (RASS) target of 0 to –1,22 unless the consultant intensivist responsible for 
clinical management decided a deeper level of sedation was needed on a given day. RASS 
was assessed every four hours. We did not use a formal pain score and analgesics were 
titrated according to the bedside nurse’s judgment of the patient’s level of comfort and pain. 
Weaning from ventilation was according to a standard protocol and included spontaneous 
breathing trials (Appendix). All patients were actively mobilised by the critical care 
physiotherapy team from admission using a step-wise programme according to daily clinical 
status, from passively moving the patient’s limbs to walking with assistance. ICU patients 
with RASS scores of –2 and upward were routinely sat out of bed unless there was a 
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contraindication. Episodes of agitation were managed according to a standard guideline 
(Appendix). The frequency and dose of any adjunct psychotropic or antipsychotic drugs were 
recorded. 
Plasma was collected on days three, seven, 14, 21 and 28 while they were on the ICU to 
measure creatine kinase (CK) and alanine transaminase (ALT) levels for the purposes of 
safety monitoring. The frequency of the following pre-specified adverse events were 
reported; CK over 10 times the upper limit of normal, ALT over eight times the upper limit of 
normal, patients whose CK is elevated over 10 fold who required new renal replacement 
therapy. Adverse events were assessed for up to 30 days after enrolment, for seriousness, 
relationship to the study drug and expectedness. 
Outcomes 
The primary outcome was delirium-free and coma-free days, defined as the number of days 
in the first 14 days after randomisation during which the patient was alive without delirium 
and not in coma from any cause. Patients who died within the 14-day study period were 
recorded as having zero days free of delirium and coma. The incorporation of delirium-free 
and coma-free days was a means of having a measure of normal or returning to normal 
brain function, where being assessed as confusion assessment method-ICU (CAM-ICU) 
negative was defined as normal.23 The recording of patients who die within the study period 
as having zero days free of delirium or coma is to address the situation where an 
intervention may increase the number of delirium-free and coma-free days but causes harm 
and increases mortality. 
Secondary outcomes were delirium-free and coma-free days to day 28, ventilator-free days 
to day 28, mortality at six months, length of critical care and hospital stay, and safety with 
regard to elevated CK and ALT, and serious adverse events attributed to study drug. We 
defined ventilator-free days as the number of calendar days after a patient started 
unassisted breathing, for patients who survived at least 48 consecutive hours after the start 
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of unassisted breathing. Patients who died within 28 days of randomisation were counted as 
having no delirium-free and coma-free days or ventilator-free days.  
Cognitive outcomes at six months were assessed by use of the Brief Test of Adult Cognition 
by Telephone (BTACT).24 The BTACT assesses multiple dimensions central for effective 
cognitive functioning including episodic memory, working memory, reasoning, verbal fluency, 
and executive function. In addition the Informant Questionnaire on Cognitive Decline in the 
Elderly (IQCODE) at baseline was compared with IQCODE data at six month follow up.25 
Cognitive outcome data was only collected from survivors recruited up until 1st February 
2016 to ensure the trial was completed within the time window defined by the available 
funding.  
Patients were defined as delirious if they were assessed with a RASS of –2 to +4, and 
screened positive for delirium by the bedside nurse using the confusion assessment method-
ICU (CAM-ICU). Patients with a RASS score of –3 to –5 were classified as if in a coma, 
irrespective of whether the state was induced by disease or sedation, and therefore unable 
to be assessed (UTA) for delirium. While the validation studies for the CAM-ICU have 
demonstrated that delirium can be diagnosed in patients of RASS -3 (movement or eye 
opening to voice but no eye contact) at our centre, along with other centres,26 we routinely 
classify a patient at RASS -3 as unable to be assessed (usually due to sedation). This unit 
decision was made because identifying a patient as ‘unable to assess’ acts as a prompt to 
the clinical staff to manage the level of sedation to enable patient screening for delirium at 
the same moving the patient out of a harmful level of sedation. RASS -3 is known to be 
associated with delayed extubation and increased mortality. 27 Delirium was assessed using 
the CAM-ICU twice during each 12 h shift with a minimum of 4 h between the two 
assessment points. All assessments in a 24 h period needed to be negative for a patient to 
be delirium-free and coma-free. If any assessment was CAM-ICU positive in a midnight to 
midnight 24 h period, that day was recorded as “with delirium”. 
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As part of the annual educational programme for unit nursing staff there is regular in house 
training on screening for delirium using the CAM-ICU, demonstrations every six weeks, ad-
hoc spot checks and one to one training of new staff. 
Statistical analysis 
The sample size calculation for this study has been initially based on data from the 
Awakening and Breathing Controlled trial published in 2008, using the mean delirium- and 
coma-free days of 10 at 28 days in patients in the standard care group.28 The database for 
the observational ‘Bringing to Light the Risk Factors and Incidence of Neuropsychological 
Dysfunction in ICU Survivors (BRAIN-ICU) Study’ showed a standard deviation of 4·1 in 
delirium and coma free days at day 14 in a similar cohort.2 Assuming this standard deviation, 
and a type I error of 0.05 and 80% power, a sample size of 64 patients per group was 
powered to detect a difference of approximately two delirium-free, coma-free days between 
the intervention and control groups, or approximately 0·5 SD. Allowing for an estimated 10% 
loss to follow-up, the sample size required was 142. nQuery AdvisoR version 4.0 was used 
for the sample size analysis (Elashoff, JD 2000). Analyses were conducted on all outcome 
data obtained from all participants as randomised and regardless of protocol adherence, i.e. 
intention to treat analysis. 
The primary outcome (delirium-coma free days) has a heavily skewed distribution (generally 
bimodal with peaks at 0 and 14 days). The primary outcome was analysed using an 
independent samples t-test. A secondary analysis of the primary outcome measure involving 
a bootstrapped t-test was also conducted to support the findings of the original analysis. 
Further to recommendations by Colantuoni and others on statistical methods for evaluating 
delirium in the ICU, a further analysis using a joint modelling approach via the R statistical 
package frailty pack was included in the statistical analysis plan and conducted.29 This was 
in response to the problems that exist when using delirium-free days as an endpoint 
including the assumption of being delirium-free on discharge and the complication presented 
by days in coma. For each patient days in delirium, delirium-free and days of exposure (not 
in coma) are calculated. Instead of presenting delirium over 14 days (the primary outcome) 
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as a single value, this approach combined two survival models: one for the repeated daily 
indicator of delirium and another for the terminating event of ICU discharge or death. A 
random effect (frailty) is included in the survival model linking all delirium events and the 
terminating event. 
ANCOVA was used to adjust for baseline severity of illness (Sepsis-related Organ Failure 
Assessment SOFA) and chance of delirium development for the primary outcome and to 
adjust for baseline IQCODE for the 6 month IQCODE.30 Dichotomous outcomes were 
analysed using risk ratios and 95% confidence intervals, where appropriate. Time to event 
outcomes such as duration of hospital stay were analysed by survival methods and reported 
as hazard ratios and 95% CI’s. Primary analyses were based on patients with outcome data 
(i.e. available case analysis). All analyses were conducted at the 5% level of significance. 
As ventilator free days and organ failure free days have a bimodal distribution, the groups 
were initially analysed by t-test with difference in means and 95% confidence intervals (CI) 
presented. A secondary analysis of these outcome measures involving a bootstrapped t-test 
was also conducted to support the findings of the t-tests. In all analyses statistical diagnostic 
methods were used to check for violations of the assumptions, and transformations were 
performed where required. Time-to-event data were presented using Kaplan-Meier plots. In 
all time-to-event analyses, patients who had not experienced the event in question were 
censored on the date last seen or 60 days. Time-to-event data was tested using a log-rank 
χ2 test. Hazard ratios (HRs) were calculated to test the difference between the treatment 
arms.  All HRs are presented with a 2-sided 95% CI. Median follow-up time was calculated. 
The BTACT composite score was calculated by averaging the standardised values of each 
variable, and then standardising that mean score.31  
Role of funding source 
 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. VJP, CM, and DFM had access to the raw data. The 
corresponding author (VJP) had full access to all data and final responsibility for the decision 
to submit for publication. 
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Results 
 
Between 1st February 2013 and 29th July 2016, 1164 patients were screened and 142 
patients were enrolled as planned; 71 patients were allocated to placebo and 71 to 
simvastatin (figure 1). 
The two groups were similar at baseline with regard to demographics, severity of illness, ICU 
admission diagnoses and predicted risk of delirium on admission (table 1). The mean ± SD 
number of days on treatment was 7·9 ± 6·6 in the simvastatin group and 10·1 ±7·8 in the 
placebo group which was not statistically significantly different (p=0.07).  The mean ± SD 
number of days from ICU admission to first dose of study drug was 1.7 ±0.8 in the 
simvastatin group and 1.6 ± 0.9 in the placebo group.  The reason study drug was 
·discontinued in the majority of patients was discharge from critical care or discontinuation of 
active treatment (table 2). Vasopressor therapy was also similar between groups with 
55(77.5%) receiving at least 1 type of vasopressor therapy on at least one day in the 
placebo group and 52(73.2%) in the simvastatin arm. 
Outcomes 
The mean number of days alive without delirium and without coma at day 14 did not differ 
significantly between the two groups (5·7 ± 5·1 days with simvastatin and 6·1 ± 5·2 days 
with placebo; mean difference, 0·4 days [95% CI, -1·3 to 2·1]; P = 0.66 using a two-sample 
t-test). There was also no significant difference in the number of days alive without delirium 
and without coma after adjustment for the baseline SOFA score and risk of delirium (mean 
difference 0·42 days [95% CI, -1·2 to 2·0]; P = 0·60). In addition using the joint modelling 
approach combining two survival models, one for the repeated (recurrent) daily indicator of 
delirium and another for the terminating event, after which patients can no longer be 
assessed for delirium, of ICU discharge or death there was no difference between the two 
groups (table 3). 
The number of days assessed as spent in delirium (as opposed to coma or normal) did not 
differ between the two groups (mean 5·6 ± 4.3 in the simvastatin group vs 5·5± 4·5 days in 
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the placebo group; p=0·92). In addition there was no difference in the number of patients 
alive without delirium and without coma between the groups by study day for each of the first 
14 days (Appendix Table 1)  
A post-hoc analysis of patients who were not CAM-ICU positive (ie were CAM-ICU negative 
or unable to assess due to coma) at randomisation showed no difference in the mean 
delirium-free, coma-free days at 14 days between the groups (Appendix Table 2). 
A post-hoc analysis in 41 patients who had sepsis and/or ARDS on admission also showed 
no difference in the mean delirium-free, coma-free days at 14 days between the groups 
(Appendix Table 3).  
There were no differences in secondary outcomes, including ventilator-free days, length of 
critical care stay, length of hospital stay, and all cause mortality at six months (table 3, 
figures 2 and 3). Cognitive outcomes were available at 6 months on 42 survivors. There was 
no difference in the BTACT composite scores (-0·2 in the simvastatin compared to 0·1 in the 
placebo group; mean difference 0·3, 95% CI 0·0 to 0·6, p = 0·1), or the difference between 
the IQCODE at baseline and six month follow up between the groups (Table 4). 
The most common adverse event was a rise in creatine kinase to over 10 times the upper 
limit of normal with eight (11·3%) in the simvastatin group versus 3 (4·2%) in the placebo 
group. There was no difference in the frequency of a rise in alanine transaminase to over 
eight times the upper limit of normal with two (2·8%) in the simvastatin group versus three 
(4·2%) in the placebo group. No serious adverse events were attributable to the study drug.  
As CRP data decreased over time due to the effects of patients being discharged or dying 
within the study period a linear mixed model was applied to compare changes in CRP by 
group and over time. This model takes into account all available data, allows for missing 
values, and estimates fixed effects while adjusting for correlation due to repeated 
measurements on each subject. Although CRP levels decreased over time there was no 
difference between the treatment groups (figure 5).  
Additional investigation into biological mechanisms including the measurement of plasma 
inflammatory response biomarkers are listed in the study protocol but are not reported in this 
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paper. 
 
Discussion 
 
In this study, early treatment with simvastatin did not increase the number of days critically ill 
patients needing mechanical ventilation spent without delirium or coma. The average 
duration of delirium in these patients was approximately six days in both groups. 
Furthermore, simvastatin did not have an effect on any secondary clinical outcomes. 
This is the first prospective, randomised double-blind and placebo-controlled trial to 
determine if administration of a statin drug impacts on brain dysfunction in critical illness. To 
address the issues regarding delirium and coma, which may or may not be part of a 
spectrum, we chose the outcome of being free of delirium and coma to incorporate an 
overall indicator of brain dysfunction throughout a patient’s critical illness. The mean duration 
of coma in study patients was 1.4 days in the simvastatin group vs. 0.9 days in the placebo 
group, and there were two patients, one in each group, who were persistently assessed as in 
coma throughout the study period. 
The drivers for delirium in critically ill patients occur early, and are multiple including sepsis, 
renal failure, hepatic impairment, sedative exposure. Some drivers take time to resolve. It is 
possible that any anti-inflammatory effect of simvastatin leading to a reduction in delirium is 
overwhelmed in the critically ill by these other confounding factors. The magnitude and 
duration of any anti-inflammatory effect in order to reduce delirium may have been 
inadequate in this patient population. This would be supported by the fact that there was no 
difference in patient’s serum CRP levels between the two groups through to 14 days 
following randomisation. The six month mortality was higher in the simvastatin group 
patients but did not reach significance and would suggest that there are no longer term 
benefits with regard to persistent subclinical inflammation postulated as a contributing factor 
to long term mortality following critical illness.32 There was no difference in cognitive 
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outcomes at six months, which would be in keeping with the absence of any acute effect on 
delirium. 
The pathophysiology of delirium remains unclear although it is believed that 
neuroinflammation is important. Those patients who develop delirium, but then it quickly 
subsides, may not have significant neuroinflammation and therefore would not benefit. It 
may be that there are other non-inflammatory factors that maintain delirium in the absence 
or reduction of neuro-inflammation.  
The strengths of this study include that patients were started on the study drug early 
regardless of coma or delirium status to maximize any benefit there may have been for 
prevention the development of more delirium or a decrease in the delirium days. This trial is, 
essentially, a delirium reduction trial; ie the aim was to determine if simvastatin would reduce 
delirium developing or persisting in patients at high risk of delirium. The study recruited a 
population similar to the population used to generate the data used in the sample size 
calculation therefore there is no reason to believe that the trial is not powered for the 
outcomes as planned. There was no indication of imbalance in baseline variables measured, 
including predicted risk of delirium and history of alcohol dependency. The low mean number 
of days spent in coma in the first 14 days, 1 day [S.D 1·4] in the simvastatin group vs 0·9 
day [S.D 1·5] in the placebo group) suggests that patients were managed in keeping with a 
RASS range of 0 to –2, ie, not deeply sedated.  
The study has several limitations. We did not use a marker of simvastatin absorption, 
however prior studies in the critically ill indicate that simvastatin 80mg daily administered 
enterally produces systemic drug concentrations that are in the high therapeutic range, and 
that drug absorption is seen even in patients with high nasogastric aspirates.33  
There was a 72 hour window following admission by which time the patients had to be 
recruited and mean (sd) time in days from admission to the first study drug for the 
simvastatin arm was 1·7(0·8) and in the placebo arm was 1·6(0·9).  It is possible that the 
neuroinflammation driving delirium was established before simvastatin levels in the CNS 
reached therapeutic levels. There was, however, no signal seen for delirium reduction 
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throughout the trial period and the study drug was given for up to 28 days in order that a 
delayed effect might be detected. 
This was a single site study, although the population of patients was broadly representative 
of the general adult ICU population, and on that basis we did not exclude the seven patients 
admitted with neurological injuries. Neurologic or neurosurgical patients admitted to our 
hospital requiring specialist intervention or monitoring are transferred to a London centre and 
not admitted to our ICU.  
The study population was heterogeneous and it may be a subset of critically ill patients 
exists who could benefit from routine simvastatin, although further studies would be required 
to investigate this. In common with other delirium studies in critically ill patients we used a 
valid instrument to determine the presence of coma or delirium and used the combination of 
the absence of coma and delirium as indicative of a patient’s brain recovering towards a 
normal state. This is a constraint as it is not possible to be confident regarding the 
significance of a coma state in many ICU patients although it is known that deep sedation is 
a predictor of adverse outcomes.  
The bedside nurse, rather than a skilled study investigator undertook the delirium screening. 
Delirium screening is embedded in routine practice at our centre, and there is evidence that 
sensitivity is improved in centres that use the CAM-ICU to guide clinical practice.34 In 
addition it meant regular screening was spread throughout any 24-hour period and was not 
restricted to daytime hours. Given the high detection rate of delirium it is unlikely that the use 
of a delirium assessment protocol would have found delirium missed using the CAM-ICU 
alone.35 The confusion assessment method-ICU (CAM-ICU) is a reliable tool recommended 
for use in this patient population in the USA Clinical Practice Guidelines for the Management 
of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit and in the UK 
National Institute for Health and Care Excellence, Delirium: prevention, diagnosis and 
management guidelines.36,37 .A multi-centre European trial, however, concluded that 
specificity of the CAM-ICU as performed in routine practice was high but sensitivity is low.38 
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There was an assumption that once a patient was discharged from ICU, they were free of 
delirium. We also used the joint modelling approach, which makes no assumption about 
delirium for patients who are discharged from ICU and there was no evidence of any 
treatment effect with simvastatin. 29 
The incidence of delirium is recorded at 93% in the simvastatin group and 94% in the 
placebo group with the predicted prevalence on admission of 70.9%. These data are similar 
to those recorded in our Hope-ICU trial.39 Comparable incidences have been reported in 
centres that undertake robust delirium screening, for instance van den Boogaard et al in a 
before and after haloperidol prophylaxis study documented an incidence of 90% in one study 
group and 97% in high risk patients.40 The high admission prevalence may be due in part to 
our unit practice of targeting early light sedation as compared with other studies that report 
admission prevalence where the majority of patients were in coma and therefore could not 
be assessed for delirium. The SPICE/ANZICS observational trial of sedation practice 
reported that at four hours after starting mechanical ventilation most patients (191 [76%]) 
were deeply sedated (RASS -3 to -5).27 Deep sedation continued throughout the first 48 
hours in 171 (68%) patients. The SPICE group found similar findings in a prospective 
longitudinal multicentre cohort study in Malaysia with deep sedation reported in 182 (71%) of 
patients at first assessment and in 159 (61%) of patients and 1,658 (59%) of RASS 
assessments at 48 hours.41  
The low numbers of patients assessed as free of delirium and coma could also be due to the 
frequency and timing of RASS and CAM-ICU assessments; study patients were assessed 
four times daily and only needed to screen positive once for delirium for that day, to count as 
not being delirium-free. It is routine practice at our centre that CAM-ICU assessments are 
undertaken as the nurse detects a change in the patient’s mental status. It is likely that 
delirium assessments were done as the patient’s level of arousal and sedation were 
changing and that in the earliest stages of waking up they were inattentive with a reduced 
level of arousal. Patel and others study demonstrated that in 12% of patients in whom 
sedation was stopped for two hours will revert from screening positive for delirium using the 
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CAM-ICU to negative.42 Nine patients in the placebo arm and six patients in the simvastatin 
arm had one day of delirium, which would be consistent with the Patel findings. It is also 
noteworthy that in our study only 43 (61%) in each group had days in delirium when not on 
sedation. Finally, the CAM-ICU, unlike the Intensive Care Delirium Screening Checklist 
(ICDSC), does not capture delirium severity. Grading delirium severity would have added 
more context to the prevalence data in this study, and this is recognized as a limitation.  
Other randomised controlled placebo-controlled drug trials aimed at the prevention or 
treatment of delirium using pharmacological interventions i.e. antipsychotics or melatonin, 
have similarly showed no benefit. 38,43,44 Rivastigmine did not decrease delirium and might 
increase mortality.45There is a continued need to explore pharmacological interventions to 
modify delirium in critically ill patients in clinical practice. Delirium, however, is a syndrome 
with any number of causes, and there is a need to develop prognostic and predictive 
enrichment strategies, such as identifying valid biomarkers, in order to design more efficient 
studies in those subgroups most likely to benefit powered for patient-centred outcomes. 
 However, in addition efforts need to be made within individual units to use non-
pharmacological strategies believed to minimise the risk in non-ICU patients developing and 
remaining in delirium.46-47  
In conclusion our study showed that simvastatin, as compared with placebo, did not increase 
the number of days critically ill patients spend without coma or delirium, although it had an 
acceptable safety profile. These results do not support the use of simvastatin in the 
management of delirium. 
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Table 1. Baseline demographic and clinical characteristics 
 
 Simvastatin 
n = 71  
Placebo 
n = 71 
Age (years) 61.9±15.3 62.1 ± 17.3 
Gender          Male 
                     Female 
45(63.4%) 
26(36.6%) 
37(52.1%) 
34(47.9%) 
Diagnosis* 
                         Sepsis &/ ARDS 
              Pneumonia 
                           MI or CCF 
                           Renal or hepatic failure 
                           COPD 
                           Haemorrhage 
                           Drug Overdose 
                           Trauma 
                           Other 
 
23 (32.4%)        
33 (46.5%) 
2 (2.8%) 
4 (5.6%) 
7 (9.9%) 
1 (1.4%) 
3 (4.2%) 
0 (0%) 
19 (26.8%) 
 
18 (25.4%) 
30 (42.3%) 
3 (4.2%)  
4 (5.6%) 
3 (4.2%) 
1 (1.4%) 
6 (8.5%) 
0 (0%) 
17 (23.9%) 
IQCODE Score n=67 
3.2±0.4 
n=60 
3.1±0.3 
RASS Score † 
           Lowest 
                   Highest 
 
-4(-4,-3) 
1(-1,2) 
 
-4(-4,-3) 
1(-1,2) 
CAM-ICU Status 
                    Positive 
                    Negative 
                    Unable to assess 
 
56(78.9%) 
0(0.0%) 
15(21.1%) 
 
56(78.9%) 
4(5.6%) 
11(15.5%) 
Predeliric Diagnose Group 
                          Surgical 
                          Medical 
                          Trauma 
                          Neurology/Neurosurgical 
 
19(26.8%) 
48(67.6%) 
0 
4(5.6%) 
 
17(23.9%) 
50(70.4%) 
1(1.4%) 
3(4.2%) 
Highest Creatinine (Umol/L) 111.6±73.7 118.5±104.9 
Highest Bilirubin (Umol/L) 31.0±68.6 20.5±25.6 
CRP (mg/L) 208.0±169.0 212.7±155.6 
Fentanyl Total Dose (mgs) 0.6±0.7 0.6±0.7 
Propofol Total Dose (mgs) 700.6±778.8 821.5±936.9 
APACHE II Score 17.2±5.3 16.7±6.4 
PRE-DELIRIC: risk of delirium development (%) 70.9±26.9 70.9±24.5 
Alcohol Abuse present 
                    Yes 
                     No                          
 
13(18.3%) 
58(81.7%) 
 
15(21.1%) 
56(78.9%) 
Total SOFA Score 8.8±3.7 
n=70 
8.9±3.1 
n=71 
CK (U/L) 240.4±294.7 219.7±250.0 
ALT (U/L) 65.0±63.8 62.6±64.4 
 
* Patients can have more than 1 diagnosis  
† Median(IQR) presented  
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Table 2: Treatment after Trial Entry 
 
 Simvastatin 
n = 71  
Placebo 
n = 71  
Study drug given (No. of patients receiving at least one dose) 
No. of days on treatment* 
71 
7.9±6.6 
71 
10.1±7.8 
Reasons for termination of study drug 
 28 days after randomisation 
 Creatine Kinase>10 times upper limit  normal 
 ALT>8 times upper limit  normal  
 Development of a clinical condition requiring immediate treatment 
with statin 
         Death 
 Discontinuation of active treatment 
      Discharge from Critical Care 
 Request for discontinuation by patient or legal 
 representative 
 Request for discontinuation by attending clinician 
        Contraindication to enteral drug administration 
 Other 
 
6(8.5%) 
8(11.3%) 
2(2.8%) 
0(0.0%) 
 
5(7.0%) 
10(14.1%) 
33(46.5%) 
4(5.6%) 
 
1(1.4%) 
0(0.0%) 
2(2.8%) 
 
4(5.6%) 
3(4.2%) 
3(4.2%) 
0(0.0%) 
 
4(5.6%) 
11(15.5%) 
44(62.0%) 
3(4.2%) 
 
0(0.0%) 
0(0.0%) 
0(0.0%) 
 
*Mean ± SD no. of days on treatment 
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Table 3. Outcome measures 
 
 Simvastatin 
n=71  
 
Placebo 
n=71  
Difference / Risk Ratio 
(95% CI) 
p-value 
Primary outcome; Delirium/Coma free to 14 days 
post randomisation* 
 
Two-sample t-test  
Bootstrap t-test (95% bias corrected CI) 
 
HR (95% CI) from Joint modelling approach 
using frailty pack in R†† 
Recurrences 
Terminal Event 
               Assignment (Simvastatin) 
               Type (Death) ††† 
               Assignment*Type 
 
 
 
 
5.7±5.1 
 
 
 
 
 
6.1±5.2 
 
 
 
 
 
0.4(-1.3, 2.1) 
0.4(-1.3, 2.0)  
 
 
 
1.1 (0.9,1.2) 
 
1.3 (0.8,2.0) 
3.6 (1.1,11.8) 
0.7 (0.2,3.3) 
 
 
 
0.66  
0.65 
 
 
 
0.33 
 
0.25 
0.03 
0.69 
 
Delirium/Coma free to 28 days post randomisation* 
 
Two-sample t-test  
Bootstrap t-test (95% bias corrected CI)  
 
 
 
14.3±11.2 
 
 
15.4±10.9 
 
 
1.1(-2.6,4.7) 
1.1(-2.0,5.1) 
 
 
0.56 
0.56 
Incidence of Delirium 66(93.0%) 67(94.4%) -0.0(-0.1,0.1) 0.81 
Days in coma to 14 days 1.0±1.4 0.9±1.5 -0.1(-0.6,0.4) 0.82 
Days in coma to 28 days 1.1±1.7 1.1±1.8  0.0(-0.6,0.6) 1.00 
Days in delirium to 14 days 5.6±4.3 5.5±4.5 -0.1(-1.5,1.4) 0.92 
Days in delirium to 28 days 6.4±6.0 6.79±6.6  0.3(-1.8,2.4) 0.80 
VFDs to 28 days post randomisation* 
 
Two-sample t-test  
Bootstrap t-test (95% bias corrected CI)  
 
 
 
13.7±11.9 
 
 
15.5±11.4 
 
 
1.8(-2.1,5.6) 
1.8(-2.0,5.3) 
 
 
0.36 
0.37 
 
 
OFFDs in first 28 days* 
Two-sample t-test Bootstrap t-test (95% bias 
corrected CI)  
 
 
14.3±12.1 
 
 
15.7±11.2 
 
1.5(-2.4,5.3) 
1.5(-2.2,5.0) 
 
0.45 
0.43 
All cause mortality 6 months post randomisation#, ** 
 
30 (42.3%) 22 (31.0%) 
 
1.4 (0.9,2.1) 
 
0.22 
 
Length of hospital stay until death or discharge from 
point of randomisation (days) † 
20.3 ± 22.1 
13 (7,25) 
20.4 ± 16.6 
16 (9,28) 
0.2(-6.3,6.7) 
2(-2,6) 
0.96 
0.3 
Length of hospital stay until discharge from point of 
randomisation (days) † 
n=47 
23.3 ± 24.3 
16(9, 26) 
 
n=50 
23.1±16.9 
18(12,34) 
 
 
-0.2(-8.6,8.2) 
2(-3,7) 
 
0.97 
0.34 
IQCODE difference from baseline to 6 months£ 3.0±0.5 n=21 3.1±0.7 n=27 0.0(-0.4,0.4) 0.99 
 
Mean ±SD presented for treatment arms and Difference (95%CI) from t-test unless indicated otherwise.  
*Results from bootstrapped t-test (Delirium/Coma free days, Organ Failure free days and Ventilator Free days 
(VFDs)) and joint modelling approach (Delirium/Coma free days only) using frailty pack also presented 
#
No.(%) for treatment arms and Risk Ratio and 95% CI presented 
**p-value from log-rank χ² presented 
† Mean ± SD and the median (IQR) for duration of hospital stay until death or discharge for all patients and 
until discharge only. Hodges-Lehmann difference (95%CI) presented for median(IQR) Mann-Whitney p-value 
presented. 
††The terminal event model included assignment (treatment arm), type (death or discharge) and 
type*assignment. 
†††There were only 8 patients included in the frailty model who had type=death prior to 14 days resulting in a 
wide 95% CI. 
£
Difference(95%CI) from ANCOVA adjusting for baseline IQCODE 
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Table 4 Brief Test of Adult Cognition by Telephone (BTACT) outcomes at six months 
Measure Simvastatin Placebo Difference   
(95% CI)** 
p-value 
Word list recall (WLR) - proportion on 
15 
N=18 
0.4 ± 0.2 (0,0.8) 
N=24 
0.4 ± 0.2 (0.1,0.9) 
  
Digits backwards (DB) – longest correct N=18  
4.4 ± 1.7 (2,8) 
N=24 
5.4 ± 1.9 (2,8) 
  
Category fluency (CF)– number 
produced 
N=18  
17.0 ± 4.9 (7,26) 
N=24 
18.2 ± 4.5 (9,27) 
  
Number series (NS) - proportion on 5 N=16  
0.4 ± 0.3 (0,1) 
N=22 
0.5 ±  0.3 (0,1) 
  
Backward counting (BC) – number 
reached from 100 
N=18 
66.2 ± 11.6 (45,86) 
N=23 
71.8 ± 7.5 (61,91) 
  
Short delay recall (SDR) - proportion on 
15 
N=18 
0.2 ± 0.2 (0,0.6) 
N=22 
0.3 ± 0.2 (0.0, 0.7) 
  
Stop and Go Switch Task (SGST)–
Average Standardised scores* 
N=18 
-0.1 ± 1.1 (-4.3, 0.4)  
N=23 
0.0 ± 0.8 (-2.5,0.4) 
  
BTACT Composite – Average 
Standardised Scores* 
N=18 
-0.2 ± 0.5 (-1.6, 0.6) 
N=24 
0.1 ± 0.5 (-1.0, 1.3) 
0.3(0.0, 0.6) 0.1 
*SGST average and BTACT composite were calculated based on no. of tasks completed. 
**Difference (95%CI) from t-test 
Mean ± SD (min, max) presented 
 
 
